Safety and Immunogenicity of the 23-Valent Pneumococcal Polysaccharide Vaccine at 12 months of age, following One, Two, or Threes Doses of the 7-valent Pneumococcal Conjugate Vaccine in Infancy

• Published in: Vaccine Vol. 28; no. 18; pp. 3086 - 3094
• Main Authors: Russell, F.M., Licciardi, P.V., Balloch, A., Biaukula, V., Tikoduadua, L., Carapetis, J.R., Nelson, J., Jenney, A.W.J., Waqatakirewa, L., Colquhoun, S., Cheung, Y.B., Tang, M.L.K., Mulholland, E.K.
• Format: Journal Article
• Language: English
• Published: 01.03.2010
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2010.02.065

Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p<0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group.